ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR
ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR
批准号:
3492886
负责人:
CHI-MING LIANG
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-09-30 至 1993-03-31
关键词:
antibody antigen antibody reaction basement membrane chromatography collagenase diagnosis design /evaluation diagnostic tests enzyme linked immunosorbent assay flow cytometry human tissue hybridomas immunocytochemistry immunoglobulin isotypes immunoprecipitation laboratory mouse method development monoclonal antibody protease inhibitor radioimmunoassay western blottings
中文摘要
基底膜的降解对白细胞的增殖具有重要作用
迁移、组织重塑、伤口愈合、血管生成和肿瘤
入侵IV型胶原是基底膜的主要成分,
由IV型胶原酶(CIVase)降解,CIVase通常存在于
潜伏形式潜伏的CIV酶可以在体内被激活为活性的CIV酶。
其活性可由内源性组织抑制剂调节,
Ⅱ型金属蛋白酶(TIMP 2)。到目前为止,还没有具体的
商业上基于生物、酶或抗体的诊断试剂盒
可用于测定CIVase或TIMP 2,具有可接受的灵敏度。我们
最近已经产生了针对CIVase的单克隆抗体(mAb)。
这些单克隆抗体已通过免疫沉淀,Western印迹,
CIVase的免疫细胞化学标记。我们将使用类似的
产生抗TIMP 2 mAb的方法,并使用这些mAb开发
定量酶联免疫吸附测定(ELISA),
免疫组化和流式细胞术检测CIVase,
TIMP 2在人体体液和组织中的水平。在第二阶段,我们将
使用这些mAb评价CIVase和
疾病的预后水平,包括
基底膜我们还将分离编码这些抗-
CIVase和抗TIMP 2 mAb显示中和活性以产生
单链抗原结合蛋白或人源化嵌合抗体。
这些分子将被测试用于伤口的潜在治疗用途。
愈合、血管生成、类风湿性关节炎的治疗和预防
癌症转移的可能性
英文摘要
The degradation of basement membrane is important for leukocyte
migration, tissue remodeling, wound healing, angiogenesis and tumor
invasion. Type IV collagen, the major component of basement membrane, is
degraded by type IV collagenase (CIVase) which usually exists in a
latent form. The latent CIVase can be activated in vivo to an active
form whose activity can be regulated by endogenous tissue inhibitor of
metalloproteinase type II (TIMP2). As yet there is no specific
biological, enzymatic or antibody based diagnostic kit commercially
available with acceptable sensitivity for assaying CIVase or TIMP2. We
have recently generated monoclonal antibodies (mAbs) against CIVase.
These mAbs have been characterized by immunoprecipitation, Western blot,
and immunocytochemical labeling of CIVase. We will use a similar
approach to generate anti-TIMP2 mAbs and use these mAbs to develop
quantitative enzyme-linked immunosorbent assay (ELISA),
immunohistochemical and flow cytometry test for examining CIVase and
TIMP2 level in the human body fluids and tissues. In phase II, we will
use these mAbs to evaluate clinical correlations between CIVase and
prognosis levels of patients with diseases involving the breakdown of
basement membrane. We will also isolate cDNA coding for these anti-
CIVase and anti-TIMP2 mAbs that show neutralization activity to generate
single chain antigen-binding proteins or humanized chimeric antibodies.
These molecules will be tested for potential therapeutic uses in wound
healing, angiogenesis, treatment of rheumatoid arthritis and prevention
of cancer metastasis.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
海外基金